Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of ALectinib as NEO-adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase-positive (ALK+) Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): ALNEO Trial

NCT05015010 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT05015010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05015010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of ALectinib as NEO-adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase-positive (ALK+) Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): ALNEO Trial
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2021
Completion date
December 28, 2026
Enrollment
33 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer